. 2022 May 16;4(3):100181. doi: 10.1016/j.opresp.2022.100181

Table 1.

Disease fraction attributable to the different pneumococcal vaccines in adults in Spain.49, 50

	PCV13	PCV15	PCV20	PPSV23
All-cause CAP^a	12.9%	14.5%	23.8%	NA
Pneumococcal CAP^a	38.05%	42.7%	69.95%	NA
IPD^b	25%	31%	62%	70%

CAP: Community Acquired Pneumonia, IPD: invasive pneumococcal disease, PCV13: 13-valent pneumococcal conjugate vaccine, PCV15: 15-valent pneumococcal conjugate vaccine, PCV20: 20-valent pneumococcal conjugate vaccine, PPSV23: 23-valent pneumococcal polysaccharide vaccine, NA: not applicable.

Adults over 18, based on 2016–2018 data.

Adults over 65, based on 2019 data.